PZLV
PZENA US Large Cap Value ETF
PZENA US Large Cap Value ETF seeks to provide long-term capital appreciation by investing primarily in large-cap U.S. value stocks that are undervalued relative to their fundamental worth.
US
EQUITY
Active
MANAGEMENT STYLE
$ 72.7 M
ASSETS UNDER MGMT
60 bp
EXPENSES
Fund Basics
| Inception date | Apr 01, 2026 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| BAXTER INTERNATIONAL INC | 4.6 % |
| COREBRIDGE FINANCIAL INC | 4.6 % |
| HUMANA INC | 4.1 % |
| DOLLAR GENERAL CORP | 3.8 % |
| LEAR CORP | 3.4 % |
| ROBERT HALF INTL INC | 3.4 % |
| FRESENIUS MEDICAL CARE-ADR | 3.3 % |
| CVS CAREMARK CORP | 3.3 % |
| COGNIZANT TECH SOLUTIONS-A | 3.2 % |
| CDW CORP/DE | 3.2 % |
Constituent Breakdown
| Number of holdings | 40 |
| Herfindahl-Hirschman Index | 279 |
| Wgt avg mkt cap (mns) | $47,852 |
| Large cap (>$10bn) | 73.3% |
| Mid cap ($2-10bn) | 22.5% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 95.6% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 83.8 % |
 |
GERMANY | 3.3 % |
 |
FRANCE | 2.8 % |
 |
BERMUDA | 2.8 % |
 |
CANADA | 2.5 % |
 |
IRELAND | 1.9 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -- | -- | -- | -- | -- | -- | -- | 18.9% |
| Dividend Yield | -- | -- | -- | -- | -- | -- | -- | 0.0% |
| Total Returns | -- | -- | -- | -- | -- | -- | -- | 18.9% | Ann. Volatility | -- | -- | -- | -- | -- | -- | -- | 14.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.00 | 0% |
| MSCI EAFE | 0.00 | 0% |
| MSCI Emg Mkts | 0.00 | 0% |
Liquidity Measures
| Avg. volume (000) | 2 |
| ADV traded (mns) | $0 |
| Turnover | 0.1% |
| Avg. Bid/Ask (% of price) | 0.21% |
Technical Indicators
| 30d moving avg. (EMA) | $31.14 |
| Relative strength (RSI) | 58 |
| MACD/Signal | 0.31/0.24 |
| Bollinger Bands (Upper/Lower) | $32.36/$29.95 |
| Short interest (% of AUM) | 0.2% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PZLV |
Expenses vs. PZLV |
ALTAR Score™ vs. PZLV |
|---|---|---|---|---|
| BUSA | Brandes U.S. Value ETF | 16.9% | 0 bp | -1.5% |
| DIVB | iShares Core Dividend ETF | 15.5% | -55 bp | -1.8% |
| CVAR | Cultivar ETF | 15.3% | +27 bp | -2.7% |
| BLCV | iShares Large Cap Value Active ETF | 13.7% | -5 bp | -4.4% |
| RPV | Invesco S&P 500 Pure Value ETF | 13.7% | -25 bp | -0.2% |
| DUSA | Davis Select U.S. Equity ETF | 13.5% | -1 bp | -1.5% |
| HWO | Hotchkis & Wiley Opportunities ETF | 13.3% | +33 bp | -1.5% |
| DVLU | First Trust Dorsey Wright Momentum & Value ETF | 13.1% | 0 bp | -1.1% |
| VLUE | iShares MSCI USA Value Factor ETF | 13.0% | -45 bp | -0.6% |
| PWV | Invesco Large Cap Value ETF | 12.7% | -5 bp | -1.7% |
Risk and Returns: PZLV vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/6/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
10.1%
ALTAR SCORE™
98th
PERCENTILE
SPECULATIVE
ETFRC RATING
There are 1,388 funds in the US Equity category with an average
ALTAR Score™ of 5.7% and a standard deviation
of 2.1%. PZLV's ALTAR Score™ is approximately 2.2 standard
deviations above the category average. This places PZLV in the 98th percentile
among funds in the category.
Sell-Side Consensus
$36.22
PRICE TARGET
+13.8%
UPSIDE